All adverse events, according to National Cancer Institute terminology criteria for Adverse Events (CTCAE) version 4.0
| Adverse event | Grade 1–2 (n (%)) | Grade 3 (n (%)) |
| Neutrophil count decreased | 1 (7.1) | |
| Hyperglycemia | 2 (14.3) | |
| Alkaline phosphate increased | 4 (28.5) | |
| Creatinine increased | 1 (7.1) | |
| Hypomagnesemia | 1 (7.1) | |
| Anemia | 2 (14.3) | |
| ALT increased | 2 (14.3) | |
| AST increased | 1 (7.1) | |
| Hyperglycemia | 1 (7.1) | |
| Hyponatremia | 1 (7.1) | |
| Hypokalemia | 1 (7.1) | |
| Lymphocyte count decreased | 1 (7.1) | |
| Peripheral sensory neuropathy | 1 (7.1) | |
| Abdominal pain | 1 (7.1) | |
| Colonic perforation | 1 (7.1) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase.